Multiple Myeloma at ASH 2017: Observations and Analysis

Posted by Josh Hattem on Dec 14, 2017 9:11:58 AM

There were 935 abstracts related to multiple myeloma accepted into the 2017 American Society of Hematology (ASH) Annual Meeting, or roughly one piece of new research for every 127 multiple myeloma patients in the U.S., according to the National Cancer Institute.


>
Read More

Attention Oncology Manufacturers: Customer Experience Matters

Posted by Jon Roffman on Apr 4, 2016 8:00:00 AM

What’s the experience that we want our customers to have? It’s a simple question, really, so why isn’t it front and center for marketing and sales people at oncology companies? Perhaps because being in the business of providing life-extending medicines to cancer patients, we would believe that should result in a positive customer experience. We’d at least expect an experience that’s better than, say, the next iPhone or a visit to the Magic Kingdom, and yet when you look at the Net Promoter Score for oncology manufacturers, the experience that they deliver lags woefully behind that of Apple and Disney. In fact, based on a recent research study conducted by ZS, we see that most oncology manufacturers have a negative Net Promoter Score, meaning that more of their customers have a negative experience than a positive one.


>
Read More

Oncology Pathways: Who Controls the Menu at Healthcare’s ‘Dinner for Three’?

Posted by Paul Darling on Mar 21, 2016 8:00:00 AM

In recent years, payers have made an effort to exert more control over physicians’ treatment decisions, especially in oncology. They’ve created clinical pathways that set out treatment guidelines and use prior authorizations and step therapy to encourage physicians to select payers’ preferred protocols and drugs.


>
Read More